A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis (Rm) Turbuhaler (Rm) 4.5 microg) and the fixed combination of formoterol and budesonide (Symbicort (Rm) Turbuhaler (Rm) 160/4.5 microg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma.

Trial Profile

A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis (Rm) Turbuhaler (Rm) 4.5 microg) and the fixed combination of formoterol and budesonide (Symbicort (Rm) Turbuhaler (Rm) 160/4.5 microg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Formoterol
  • Indications Allergic asthma; Asthma
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SMILDA
  • Most Recent Events

    • 01 Apr 2009 Results reported in the European Respiratory Journal.
    • 29 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top